Prosecution Insights
Last updated: April 19, 2026
Application No. 18/701,211

PERCUTANEOUS TREATMENT DEVICE AND METHOD

Non-Final OA §102§103§112
Filed
Apr 12, 2024
Examiner
FLANAGAN, BEVERLY MEINDL
Art Unit
3794
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Pulse Biosciences Inc.
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 4m
To Grant
95%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
136 granted / 191 resolved
+1.2% vs TC avg
Strong +24% interview lift
Without
With
+23.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
61 currently pending
Career history
252
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
39.7%
-0.3% vs TC avg
§102
20.7%
-19.3% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 191 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement filed August 2, 2024 has been entered and the references cited therein have been considered by the examiner. Preliminary Amendment Applicant’s preliminary amendment, filed April 12, 2024, has been entered. Accordingly, claims 1-49 are canceled; claims 50-74 are newly added. Drawings The drawings are objected to under 37 CFR 1.83(a) because they fail to show the second spacer 1054’ as described in the specification at paragraph 000119 (specifically, Figure 10D). Any structural detail that is essential for a proper understanding of the disclosed invention should be shown in the drawing. MPEP § 608.02(d). Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 55, 57 and 67-74 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 55 recites “the second electrode is configured to avoid abrupt changes in angle between walls of the tip region and tissue.” This recitation is vague and indefinite as there is no structural element recited that performs the recited function and therefore it cannot be determined what applicant intends to claim. Claims 57 and 67 recite “and/or” which renders the claim vague and indefinite as the metes and bounds of the claims cannot be determined. As claims 68-74 depend from claim 67, they are likewise rejected. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 50, 52-57, 59, 60, 65 and 66 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Willis (U.S. Patent Application Publication No. 2015/0126922). In regard to claims 50, 52-56 and 66, Willis teaches an energy delivery probe 13 for pulsed electric field ablation (see para. 0062) comprised of a handle 17 and a tip region having electrodes 4, 40 where electrode 40 is a cannula and electrode 4 is a trocar (see Figs. 1 and 5A and para. 0066). Figure 5A shows that trocar electrode 4 has a distal cutting region and a proximal non-cutting region that has a curved, conical surface (see also para. 0068). Figure 5A also shows that trocar electrode 4 has one or more blade edges extending proximally to cut tissue and the proximal non-cutting region has a smooth face extending proximally from a proximal end of the one or more blade edges where the smooth face is configured to stretch and expand tissue (see also para. 0068). The use of a trocar shape on trocar electrode 4 would inherently include three or more cutting blade edges (as is conventional in a trocar shape) and would inherently increase hoop stress as it pierces and penetrates tissue. Figure 5A also shows that the circumference of the distal cutting region is about 5% to about 50% of a full circumference of the electrode 4 at the proximal non-cutting region. In addition, Figure 5A shows that trocar electrode 4 is configured to avoid abrupt changes in an angle between the walls of the tip region and tissue as it is tapered. Figure 5A also shows that a change in angle between each of the one or more blade edges relative to a long axis of the tip region as it transitions to the smooth face is less than 20 degrees. Willis also teaches an insulation sleeve 45 that acts as a spacer between trocar electrode 4 and electrode 40 (see Fig. 5A). In regard to claim 57, Willis teaches that the trocar 4 or cannula 40 can have at least one lumen or channel that extends along the longitudinal axis of the probe 13 that can be used to deliver or withdraw fluids (see para. 0077). In regard to claim 59, see para. 0089 of Willis. In regard to claim 60, see para. 0070 of Willis. In regard to claim 65, see Fig. 5A of Willis. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 51, 58, 61-64 and 67-74 is/are rejected under 35 U.S.C. 103 as being obvious over Willis (U.S. Patent Application Publication No. 2015/0126922) in view of Danitz et al. (U.S. Patent Application Publication No. 2020/0261720). The applied reference has a common inventor and assignee with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 103 might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C.102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B); or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. See generally MPEP § 717.02. In regard to claims 67, 68 and 71, see the above rejection for claim 50. With further respect to claim 67 and in regard to claim 51, Willis is silent as to the application of sub-microsecond pulses. However, Danitz et al. teach a similar probe device utilizing sub-microsecond pulsing at a duration of less than 1000 nanoseconds for the purpose of manipulating intracellular structures (see paras. 0004, 0011 and 0134). Danitz et al. thus demonstrate that the use of sub-microsecond pulsing at a duration of less than 1000 nanoseconds is well known in the art. Accordingly, it would have been obvious for one of ordinary skill in the art at the effective filing date of the invention to equip the device of Willis with the ability to deliver sub-microsecond pulsing at a duration of less than 1000 nanoseconds in order to better manipulate intracellular structures. In regard to claims 58 and 64, see Figs. 4-5 of Davitz et al. It would have been obvious for one of ordinary skill in the art at the effective filing date of the invention to provide the device of Willis with a space that has a wider circumference than the trocar electrode 4 or the electrode 40 or that tapers as changes in the size of a prior art device are a design consideration within the skill of the art. In regard to claim 61, see Figs. 14-18 of Davitz et al. In regard to claims 62 and 70, see Fig. 13 of Danitz et al. In regard to claims 63 and 69, see Fig. 5 of Davitz et al. In regard to claims 72-74, see para. 0108 of Willis. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BEVERLY MEINDL FLANAGAN whose telephone number is (571)272-4766. The examiner can normally be reached Mon-Fri 7:30AM to 5:00PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Linda Dvorak can be reached at 571-272-4764. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BEVERLY M FLANAGAN/Primary Examiner, Art Unit 3794
Read full office action

Prosecution Timeline

Apr 12, 2024
Application Filed
Jan 09, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582467
SURGICAL INSTRUMENT WITH HOVER SENSOR AND RELATED METHODS
2y 5m to grant Granted Mar 24, 2026
Patent 12582468
APPLICATION OF NON-THERAPEUTIC WAVEFORMS WITH GRADIENT SENSING TO PREDICT PULSED FIELD ABLATION (PFA) FIELDS
2y 5m to grant Granted Mar 24, 2026
Patent 12582469
GROUPED PIN RECEPTACLE CONNECTOR FOR ABLATION CATHETER HANDLE
2y 5m to grant Granted Mar 24, 2026
Patent 12575881
CALIPER TOOL WITH TOGGLING BETWEEN MULTIPLE ABLATION MODES
2y 5m to grant Granted Mar 17, 2026
Patent 12569139
MICROSURGICAL SYSTEMS FOR PERFORMING SURGICAL PROCEEDURES
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
95%
With Interview (+23.6%)
2y 4m
Median Time to Grant
Low
PTA Risk
Based on 191 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month